Lv71
5005 积分 2021-05-28 加入
Comparative effectiveness of peroxisome proliferator–activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis
26分钟前
已完结
Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial
2天前
已完结
Seladelpar for alkaline phosphatase normalization in primary biliary cholangitis: The IDEAL phase III randomized controlled trial
5天前
已完结
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
16天前
已关闭
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
16天前
已完结
Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study
16天前
已完结
AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis
20天前
已关闭
EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis
26天前
已完结
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
2个月前
已完结
Seladelpar: First Approval
2个月前
已完结
皖公网安备34019202002308
